Iomab-B
Actinium Pharmaceuticals
['sierra ']
actinium announces positive pivotal phase 3 sierra trial results in an oral presentation at the eha 2023 congress ( ). read the news release here: $atnm #eha2023
Actinium is developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently investigating therapies in #AML #BMT $ATNM